Difference between revisions of "Temozolomide (Temodar)"

Revision as of 02:14, 21 January 2018

Also known as Temcad and Temodal.

General information

Class/mechanism: Alkylator. Temozolomide is converted in vivo to the reactive compound 5-(3-methyltriazen- 1-yl)-imidazole-4-carboxamide (MTIC). MTIC causes alkylation of DNA at the O6 and N7 positions of guanine, leading to cell damage and cell death.^[1]^[2]^[3]
Route: PO, IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.^[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

8/11/1999: Initial FDA approval

References

[insert-1] 1.0 ^1.1 Temozolomide (Temodar) package insert

[2] Temozolomide (Temodar) package insert (locally hosted backup)

[3] Temodar manufacturer's website

[4] Temozolomide (Temodar) patient drug information from manufacturer

[5] Temozolomide (Temodar) patient drug information (Chemocare)

[6] Temozolomide (Temodar) patient drug information (UpToDate)

[1]

[2]

[3]

[4]

[5]

[6]

@@ Line 42: / Line 42: @@
 [[Category:Acute myeloid leukemia medications]]
 [[Category:Anaplastic glioma medications]]
-[[Category:Central nervous system (CNS) lymphoma medications]]
+[[Category:CNS lymphoma medications]]
 [[Category:Ewing's sarcoma medications]]
 [[Category:Glioblastoma medications]]